Artelo Biosciences, Inc. Common Stock
$3.94
-$0.03 (-0.76%)
$3.92Day Range$4.14
Key Statistics
Market Cap
$2.16M
Shares Outstanding
0.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 13, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$4.00
Day High
$4.14
Day Low
$3.92
Volume
29.7K
VWAP
$4.01
Prev Close
$3.97
Transactions
--
Acc. Volume
--
About Artelo Biosciences, Inc. Common Stock
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
PHARMACEUTICAL PREPARATIONSSIC 28347 employees505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075858-925-7049IPO Oct 13, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001621221
- Composite FIGI
- BBG00793XCW0
- Share Class FIGI
- BBG00793XCX9
- Ticker Root
- ARTL
- SIC Code
- 2834
About Artelo Biosciences, Inc. Common Stock (ARTL) Stock
Artelo Biosciences, Inc. Common Stock (ARTL) closed the 2026-09-18 session at $3.94, down 0.76% versus the previous close (-0.03). The stock opened at $4.00 and traded between $3.92 and $4.14 during that session. Session trading volume was 30K shares. The volume-weighted average price (VWAP) is $4.01.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Artelo Biosciences, Inc. Common Stock has a market capitalization of $2.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ARTL is listed on the XNAS exchange. The company employs approximately 7 people. Artelo Biosciences, Inc. Common Stock is headquartered in SOLANA BEACH, CA. The recorded listing date is 2015-10-13.
On this page you can find market ARTL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.